Application of dihydroartemisinin as medicament for treating triple negative breast cancer in combination with cisplatin

The invention discloses an application of dihydroartemisinin in preparation of a medicine for treating triple negative breast cancer, which is characterized in that dihydroartemisinin and cisplatin are combined to be taken by a triple negative breast cancer patient, and radiation therapy is combined to enhance the sensitivity of the triple negative breast cancer to radioactive rays. According to the application, dihydroartemisinin (DHA) and cis-platinum (DDP) are combined for use, so that the sensitivity of triple negative breast cancer cells to radioactive rays is improved, the curative effect of radiotherapy is improved, and the side effects of radiotherapy are reduced. 本发明公开一种双氢青蒿素在制造治疗三阴性乳腺癌药物中的用途，所述用途是指双氢青蒿素与顺铂联合用药方式给三阴性乳腺癌患者服用，联合放射疗法，以增强三阴性乳腺癌对放射线的敏感性。该用途通过双氢青蒿素(DHA)和顺铂(DDP)联合使用，提高三阴性乳腺癌细胞对放射射线的敏感性，从而提高放射治疗的疗效和减少放射治疗的副作用。